Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Colorectal Cancer in a Younger Population

April 2nd 2021

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.

Dr. Eng on the Rising Incidence of Early-Onset CRC

April 1st 2021

Cathy Eng, MD, FACP, FASCO, discusses the rising incidence of early-onset colorectal cancer.

Noninvasive cfDNA Blood Test for Advanced Adenoma and CRC Under Exploration

March 31st 2021

A prospective, multicenter, observational USOPTIVAL study has been initiated in the United States to examine an investigational cell-free DNA blood test to detect advanced adenoma and colorectal cancer.

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Dr. Bekaii-Saab on the Challenges of Utilizing Chemotherapy-Free Regimens in CRC

March 25th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Optimizing mCRC Treatment: Decision-Making With Patients

March 25th 2021

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Initial Strategies for Assessing and Treating mCRC

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.

FDA Grants 2 Breakthrough Device Designations to Signatera MRD Test

March 24th 2021

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies

March 23rd 2021

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

Dr. Eng Discusses the Ongoing FRESCO-2 Trial in mCRC

March 23rd 2021

Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Dr. Basu-Mallick on the Importance of Clinical Research Examining ctDNA in CRC

March 22nd 2021

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.

Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

March 19th 2021

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Tilsotolimod/Ipilimumab Fails to Improve ORR in PD-1 Refractory, Advanced Melanoma

March 19th 2021

The combination of tilsotolimod plus ipilimumab failed to improve objective response rate over ipilimumab alone in patients with advanced melanoma who are refractory to a PD-1 inhibitor, missing the primary end point of the phase 2 ILLUMINATE-301 trial.

Dr. Eng on Extended RAS Analysis Results From the EPIC Trial in mCRC

March 17th 2021

Cathy Eng, MD, FACP, FASCO, discusses results from the extended RAS analysis of the phase 3 EPIC trial in patients with metastatic colorectal cancer.

Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC

March 16th 2021

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Dr. Kazmi on Emerging Biomarkers in CRC

March 15th 2021

Syed Kazmi, MD, discusses emerging biomarkers that could help guide treatment decisions in patients with colorectal cancer.

Dr. Philip on Non-Operative Treatment Advances in CRC

March 12th 2021

Tony Philip, MD, discusses advances made in the treatment of patients with colorectal cancer.

GI Cancer Expert Is Searching for Big Leaps in Care

March 12th 2021

John L. Marshall, MD, has made it his mission to improve the lives of patients with GI cancers through innovative research, personalized medicine, and focused advocacy.

ctDNA, Total Neoadjuvant Therapy, and TAS-102 Signal a Shift in CRC Management

March 12th 2021

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.